Results 221 to 230 of about 872,419 (247)

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga   +2 more
wiley   +1 more source

DPP4 Inhibitors and Hypersensitivity Reactions: Experiences From Clinical Pharmacology and Diabetes and Allergy-Asthma Therapeutics Specialty Clinics

open access: diamond
Shambo Samrat Samajdar   +6 more
openalex   +1 more source

Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. [PDF]

open access: yesJ Clin Oncol
Tomasini P   +32 more
europepmc   +1 more source

Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics

open access: gold
Akhilesh Mishra   +10 more
openalex   +1 more source

First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1. [PDF]

open access: yesCardiovasc Res
Desai MY   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy